Concepedia

Shenghua Wen

SW

14

Publications

1K

Citations

14

H-Index

2001

Active since

Affiliations

AstraZeneca (United States)(Current)

AstraZeneca (United Kingdom)

AstraZeneca (France)

Millennium Engineering and Integration (United States)

AstraZeneca (Singapore)

Shenghua Wen is an author at AstraZeneca (United States) specializing in medicine, cell biology, and tumor microenvironment.

ORCID

Top concepts

Publications per year

2001–2022

14

Publications

14

PTEN controls tumor-induced angiogenesis

Shenghua Wen, Javor P. Stolarov, Michael P. Myers et al. · Proceedings of the National Academy of Sciences · 2001 · 244 citations · Full text

A Prostate-Specific Membrane Antigen-Targeted Monoclonal Antibody–Chemotherapeutic Conjugate Designed for the Treatment of Prostate Cancer

Michael D. Henry, Shenghua Wen, Matthew D. Silva et al. · Cancer Research · 2004 · 155 citations

A Human Monoclonal Anti-ANG2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models

Jeffrey L. Brown, Zhe Cao, Maria Pinzon-Ortiz et al. · Molecular Cancer Therapeutics · 2010 · 150 citations · Full text

, , +16

AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies

Garrett W. Rhyasen, Maureen M. Hattersley, Yi Yao et al. · Molecular Cancer Therapeutics · 2016 · 147 citations · Full text

, , +17

Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy

Claire Patterson, Srividya B. Balachander, Iain Grant et al. · Communications Biology · 2021 · 89 citations · Full text

Rows per page

1–5 of 14